119 related articles for article (PubMed ID: 38678619)
1. Analysis of the relationship between MYCN gene and serum NSE and urinary VMA levels and neuroblastoma pathological features and prognosis.
Zhang H; He X; Miao Q; Li L; Song J; Jiang X
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):134-139. PubMed ID: 38678619
[TBL] [Abstract][Full Text] [Related]
2. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
[TBL] [Abstract][Full Text] [Related]
3. A nomogram for predicting recurrence-free survival of intermediate and high-risk neuroblastoma.
Sun Q; Chen Y; Jin Q; Yuan X
Eur J Pediatr; 2022 Dec; 181(12):4135-4147. PubMed ID: 36149505
[TBL] [Abstract][Full Text] [Related]
4. Hormonal activity may predict aggressive behavior in neuroblastoma.
Zambrano E; Reyes-Múgica M
Pediatr Dev Pathol; 2002; 5(2):190-9. PubMed ID: 11910515
[TBL] [Abstract][Full Text] [Related]
5. N-myc oncogene and urinary catecholamines in children with neuroblastoma.
Barontini M; Gutiérrez MI; Levin G; Mur N; Diez B
Med Pediatr Oncol; 1993; 21(7):499-504. PubMed ID: 8341218
[TBL] [Abstract][Full Text] [Related]
6. Values of serum CA125, NSE and 24-hour urine VMA in diagnosis and prediction of treatment of paediatric neuroblastoma.
Li J; Liu X; Chen M; Wang J; Wang X
Int J Clin Pract; 2021 Dec; 75(12):e14932. PubMed ID: 34606672
[TBL] [Abstract][Full Text] [Related]
7. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening.
Iehara T; Hosoi H; Akazawa K; Matsumoto Y; Yamamoto K; Suita S; Tajiri T; Kusafuka T; Hiyama E; Kaneko M; Sasaki F; Sugimoto T; Sawada T
Br J Cancer; 2006 May; 94(10):1510-5. PubMed ID: 16670717
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic markers in infants with disseminated neuroblastoma: a retrospective analysis from the Italian Cooperative Group for Neuroblastoma.
Di Cataldo A; Dau D; Conte M; Parodi S; De Bernardi B; Giuliano M; Pession A; Viscardi E; Luksch R; Castellano A; Bertuna G; Haupt R;
Med Sci Monit; 2009 Jan; 15(1):MT11-8. PubMed ID: 19114976
[TBL] [Abstract][Full Text] [Related]
9. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of combined serum CA125, NSE and 24-hour urine VMA for the prediction of recurrence in children with neuroblastoma.
Li J; Qi Z; Chen M; Wang J; Liu X
Ital J Pediatr; 2023 Aug; 49(1):102. PubMed ID: 37620978
[TBL] [Abstract][Full Text] [Related]
11. [The prognostic effect of amplification of the MYCN oncogene in neuroblastoma. The preliminary results of the Italian Cooperative Group for Neuroblastoma (GCINB)].
Pession A; De Bernardi B; Perri P; Mazzocco K; Rondelli R; Nigro M; Iolascon A; Forni M; Basso G; Conte M
Pediatr Med Chir; 1994; 16(3):211-8. PubMed ID: 7971442
[TBL] [Abstract][Full Text] [Related]
12. Tumour markers are poor predictors for relapse or progression in neuroblastoma.
Simon T; Hero B; Hunneman DH; Berthold F
Eur J Cancer; 2003 Sep; 39(13):1899-903. PubMed ID: 12932669
[TBL] [Abstract][Full Text] [Related]
13. Serum vanillylmandelic acid/homovanillic acid contributes to prognosis estimation in patients with localised but not with metastatic neuroblastoma.
Berthold F; Hunneman DH; Harms D; Käser H; Zieschang J
Eur J Cancer; 1992; 28A(12):1950-4. PubMed ID: 1419287
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
[TBL] [Abstract][Full Text] [Related]
15. [N-myc gene copies in children with neuroblastoma and its clinical significance].
Ma XL; Gong LP; Zhou CJ; Zhang DW; Jin M; Wang HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1447-51. PubMed ID: 23257451
[TBL] [Abstract][Full Text] [Related]
16. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.
Georgantzi K; Sköldenberg EG; Stridsberg M; Kogner P; Jakobson Å; Janson ET; Christofferson RHB
Pediatr Hematol Oncol; 2018 Mar; 35(2):156-165. PubMed ID: 29737901
[TBL] [Abstract][Full Text] [Related]
18. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification.
Huang C; Jiang S; Yang J; Liao X; Li Y; Li S
Medicine (Baltimore); 2020 Jun; 99(25):e20853. PubMed ID: 32569234
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
Marrano P; Irwin MS; Thorner PS
Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
